Deal Snapshot
Frontage Acquires Majority Stake in Heyan Biotech, Expanding Early Drug Discovery Services
Monday 13 September 2021

China-based CRO Frontage Shanghai has acquired a 70% equity interest in China-based early drug discovery services specialist Wuhan Heyan Biomedical Technology Co., Ltd, the company said.

Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target-based in-vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery.

Date Published: 13/09/2021